UNSPSC 51421601: Clobetasol

This classification denotes a therapeutic glucocorticoid with the molecular formula C22H28ClFO4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier ADN79D536H, chemically known as 21-chloro-9-fluoro-11b,17-dihydroxy-16a-methylpregna-1,4-diene-3,20-dione but generally known as clobetasol, which bears US NIH Compound Identifier 32797. European Medicines Agency schedules Clobetasol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06678MIG.

UNSPSC 51421601 Clobetasol is a Commodity code that describes pharmaceutical products, but the recent state and local procurement activity associated with this code shows a significant mismatch: the only identifiable opportunity involves naloxone and drug deactivation systems, which fall outside the dermatological steroid scope of the code's nominal classification. The recent solicitation does not reflect purchasing of clobetasol or related corticosteroid preparations by state or local health agencies.

Seminole County, Florida posted an IFB (IFB60459723LAS) on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually through competitive bidding, with a response deadline of July 26, 2023, at 2:00 pm. Quarterly deliveries are required to the Seminole County Community Health Building in Sanford, with vendors responsible for all shipping and delivery costs. The contract carries a two-year initial term with one-year renewal option and includes a three-month probationary period. Bidders must meet E-Verify compliance, drug-free workplace certification, and carry workers' compensation, commercial general liability, and professional liability insurance. The procurement may be FEMA-funded, introducing federal compliance requirements including the Clean Air Act and Federal Water Pollution Control Act. This code shows little relevant recent activity aligned with its actual pharmaceutical scope; the clobetasol classification does not correlate with the naloxone-focused opportunity on file.